Synchronicity Pharma

Executive Summary

Synchronicity Pharma is a clinical-stage biotechnology company pioneering small molecule therapeutics that target the circadian clock. Founded in 2018 and headquartered in San Diego, the company exploits deep expertise in circadian biology to develop novel treatments for difficult-to-treat cancers and sleep-wake disorders associated with neurodivergence, such as autism spectrum disorder. By modulating core clock genes and proteins, Synchronicity aims to reset disrupted circadian rhythms that drive disease pathology. The company's lead programs are in preclinical or early clinical development, with a focus on oncology and neurology indications where circadian dysregulation is implicated. As a private firm, Synchronicity has not disclosed significant funding rounds or valuation, but its unique approach positions it at the intersection of chronobiology and precision medicine. Near-term value drivers include advancement of its lead candidate into Phase 1 trials and potential publication of preclinical efficacy data, which could attract partnership interest or additional financing.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for lead circadian clock modulator in oncology40% success
• Q2 2026Publication of preclinical in vivo data in sleep-wake disorder model for neurodivergence70% success
• H1 2027Series A financing or strategic partnership announcement50% success